Q1 2026 Nautilus Biotechnology Inc Earnings Call Transcript
Key Points
- Nautilus Biotechnology Inc (NAUT) is making significant progress towards commercialization, with plans to initiate a commercial launch in late 2026 and customer installations beginning in early 2027.
- The company has successfully launched its Iterative Mapping Early Access Program, with growing customer interest from academic centers, non-profit research institutions, and biopharma organizations.
- Nautilus Biotechnology Inc (NAUT) has strengthened its commercial team by hiring experienced industry veterans, including a new VP of Global Sales, to support launch activities.
- The company is advancing its scientific and technical capabilities, particularly with its Voyager platform, which is designed to execute a diverse family of iterative mapping-based assays.
- Nautilus Biotechnology Inc (NAUT) has made meaningful progress in its oncology proteoform target selection process, focusing on high-priority candidates for its next early access program expansion.
- Revenue recognition associated with the Michael J. Fox Foundation grant has been slower than anticipated due to delays related to the ongoing conflict in the Middle East.
- The company is still in the early stages of developing its commercial sales organization, with only a few members currently in place.
- Nautilus Biotechnology Inc (NAUT) is not expecting near-term revenue from its early engagements, as these are designed to enable biological discovery and support publications rather than immediate financial returns.
- There have been delays in custom reagent development from collaborators due to external conflicts, impacting the alpha-synuclein proteoform program.
- The company faces technical challenges in ensuring robust methods for validating single-molecule identifications and benchmarking them against orthogonal analysis methods.
Good day, and thank you for standing by. Welcome to the Nautilus Biotechnology first-quarter 2026 conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to our first speaker today, Ji-Yon Yi, Investor Relations. Please go ahead.
Thank you. Earlier today, Nautilus Biotechnology released financial results for the quarter ended March 31, 2026. If you haven't received this news release or if you'd like to be added to the company's distribution list, please send an e-mail to [email protected]. Joining me today from Nautilus are Sujal Patel, Co-Founder and CEO, Parag Mallick, Co-Founder and Chief Scientist; and Anna Mowry, Chief Financial Officer.
Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking within the meaning of the Federal Securities laws. These statements involve material risks and uncertainties that
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
